Christoph Hiemke

Professor of Neurochemistry

University Medical Center

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Christoph Hiemke is a Professor of Neurochemistry at the Medical Center - University Center in Germany. His research focuses on pharmacokinetic correlates of antidepressants and antipsychotics, particularly in relation to therapeutic reference ranges and adverse drug reactions. Recent publications include assessments and systematic reviews concerning escitalopram, venlafaxine, and olanzapine, among others, aimed at improving treatment strategies for depression and schizophrenia.

Articles (20)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Pierre Baumann

em. professor (professeur honoraire)

University of Lausanne

SWITZERLAND

View details

Chin B. Eap

SWITZERLAND

View details

Ansgar Klimke

Medical Director, Head of Department

GERMANY

View details

Thomas Riemer

Charité - Universitätsmedizin Berlin

GERMANY

View details

Gerhard Gründer

Heidelberg University

GERMANY

View details

Georgios Schoretsanitis

University of Zurich

SWITZERLAND

View details

Arnim Johannes Gaebler

Medizinische Fakultät der RWTH Aachen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christoph Hiemke

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Pharmacokinetic correlates of clinical response in a naturalistic sample of escitalopram-treated patients

Assessing Pharmacokinetic Correlates of Escitalopram-Related Adverse Drug Reactions.

Lower sertraline plasma concentration in patients co‐medicated with clozapine—Implications for pharmacological augmentation strategies in schizophrenia

Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations

Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.

Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication.

Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review on Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy.

Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy.

Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder.

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions.

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection.

Authors' Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation".

Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database.

Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study.

Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis.

Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.

Collaborators (7)

Pierre Baumann

Chin B. Eap

Ansgar Klimke

Thomas Riemer

Gerhard Gründer

Georgios Schoretsanitis

Arnim Johannes Gaebler

Make your next move.